The study, conducted at KGK Synergize Inc. (“KGK”), a contract research organization located in London, Ontario, was recently published in Urologic Nursing, and identifies that there was a significant change in 24-hour urine oxalate levels among two treatments. The study was conducted as a randomized, double-blind, crossover trial of vitamin C with metabolites (Ester-C®) compared to ascorbic acid in 50 healthy adults.
Subjects on a controlled diet ingested 1000 mg/day vitamin C with metabolites for 5 days and 2000 mg/day for an additional 5 days, and urine oxalate was measured. After a 7 day washout, participants repeated the same protocol (crossed over) with the alternative form of vitamin C. There was a significant change in the urine oxalate levels between the two treatments. Approximately 25% more subjects experienced a reduction in 24-hour oxalate (59% to 34%) and oxalate concentration (72% to 46%) over the 10 day period when taking vitamin C with metabolites compared to ascorbic acid.
According to Mark A. Moyad, MD, a research consultant for The Ester C Company, “these results are very promising and worthy of further clinical evaluation”.
About KGK Synergize Inc:
KGK provides contract research services to the health nutrition, biotechnology and pharmaceutical industries. These services include both pre-clinical and human clinical trials.
In addition to its contract research capabilities, KGK has a Product Development Division which brings new and innovative natural health products to the point where they are ready to be manufactured and marketed. These products include Sytrinol®, DiabetinolTM and DermytolTM.